Quantinno Capital Management LP Acquires 100,183 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Quantinno Capital Management LP raised its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 66.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 250,834 shares of the company's stock after purchasing an additional 100,183 shares during the quarter. Quantinno Capital Management LP owned approximately 0.05% of Elanco Animal Health worth $3,685,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Point72 DIFC Ltd acquired a new position in shares of Elanco Animal Health in the 3rd quarter valued at about $9,969,000. Point72 Asset Management L.P. bought a new stake in Elanco Animal Health in the third quarter worth approximately $19,708,000. Polar Asset Management Partners Inc. lifted its stake in Elanco Animal Health by 312.6% in the third quarter. Polar Asset Management Partners Inc. now owns 554,100 shares of the company's stock valued at $8,140,000 after buying an additional 419,800 shares during the period. Parkman Healthcare Partners LLC boosted its holdings in shares of Elanco Animal Health by 1.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 127,812 shares of the company's stock worth $1,878,000 after buying an additional 1,770 shares in the last quarter. Finally, Ionic Capital Management LLC acquired a new stake in shares of Elanco Animal Health during the 3rd quarter worth approximately $2,330,000. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

Shares of ELAN traded up $0.38 on Monday, reaching $12.88. 4,181,769 shares of the company's stock traded hands, compared to its average volume of 4,770,076. The stock's 50 day simple moving average is $13.43 and its two-hundred day simple moving average is $14.46. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 52-week low of $11.40 and a 52-week high of $18.80. The stock has a market cap of $6.37 billion, a PE ratio of 31.88, a PEG ratio of 2.02 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.01. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm's quarterly revenue was down 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.18 EPS. On average, analysts forecast that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ELAN shares. Leerink Partners assumed coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a "market perform" rating and a $14.00 target price on the stock. Barclays upped their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, November 8th. UBS Group started coverage on Elanco Animal Health in a research report on Monday. They set a "buy" rating and a $18.00 target price on the stock. Stifel Nicolaus reissued a "buy" rating and issued a $20.00 price target on shares of Elanco Animal Health in a research report on Thursday, September 19th. Finally, Leerink Partnrs upgraded shares of Elanco Animal Health to a "hold" rating in a report on Monday, December 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $16.75.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.